Institute of Health and Biomedical Innovation, Centre in Regenerative Medicine, Queensland University of Technology, Brisbane, Australia.
Radboud University Medical Center, Department of Cell Biology, Post 283, PO Box 9101, 6500HB Nijmegen, The Netherlands; University of Texas MD Anderson Cancer Center, Genitourinary Medical Oncology-Research, Houston, TX, USA; Cancer Genomics Center, Utrecht, The Netherlands.
Trends Biotechnol. 2018 Mar;36(3):242-251. doi: 10.1016/j.tibtech.2017.12.001. Epub 2018 Jan 5.
The laboratory mouse is widely considered as a valid and affordable model organism to study human disease. Attempts to improve the relevance of murine models for the investigation of human pathologies led to the development of various genetically engineered, xenograft and humanized mouse models. Nevertheless, most preclinical studies in mice suffer from insufficient predictive value when compared with cancer biology and therapy response of human patients. We propose an innovative strategy to improve the predictive power of preclinical cancer models. Combining (i) genomic, tissue engineering and regenerative medicine approaches for rational design of mouse models with (ii) rapid prototyping and computational benchmarking against human clinical data will enable fast and nonbiased validation of newly generated models.
实验鼠被广泛认为是研究人类疾病的有效且经济实惠的模式生物。为了提高研究人类疾病的鼠模型的相关性，人们尝试开发了各种基因工程、异种移植和人源化小鼠模型。然而，与人类患者的癌症生物学和治疗反应相比，大多数小鼠的临床前研究的预测价值都较低。我们提出了一种创新策略来提高临床前癌症模型的预测能力。将（i）基因组、组织工程和再生医学方法相结合，用于合理设计小鼠模型，（ii）快速原型制作和针对人类临床数据的计算基准测试，将使新生成的模型能够快速、无偏地得到验证。
